3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Leukemia, Myeloid, Acute
2
Recurrence
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Lymphoma, T-Cell
1
Lymphoma
1
Leukemia, Myelomonocytic, Acute
1
Leukemia, Monocytic, Acute
1
Leukemia, Megakaryoblastic, Acute
1
Leukemia, Erythroblastic, Acute
1
Leukemia
1
Interventions
Cytarabine
34
Filgrastim
14
Idarubicin
13
Etoposide
12
Busulfan
12
fludarabine phosphate
10
Peripheral Blood Stem Cell Transplantation
10
Cyclophosphamide
10
Mitoxantrone
8
Methotrexate
7
Daunorubicin
7
Cyclosporine
6
Tacrolimus
5
Radiotherapy
5
Clofarabine
5
Whole-Body Irradiation
4
Mycophenolic Acid
4
Gemtuzumab
4
Arsenic Trioxide
4
Antilymphocyte Serum
4
Topotecan
3
Imatinib Mesylate
3
Granulocyte Colony-Stimulating Factor
3
Flow Cytometry
3
Decitabine
3
eltrombopag
2
choline magnesium trisalicylate
2
aldesleukin
2
Vorinostat
2
Thiotepa
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Leukemia, Myelomonocytic, Acute
×
BI 6727
×
Clear all
NCT02527174
2017-04-05
VIAC
University of Alberta
Phase 1
Withdrawn